What is Alnylam Pharmaceuticals, Inc.'s Market Cap?

Alnylam Pharmaceuticals, Inc.'s Market Cap is $30.4B, based on as-reported figures from SEC (XBRL) filings.

What is Alnylam Pharmaceuticals, Inc.'s Trailing P/E?

Alnylam Pharmaceuticals, Inc.'s Trailing P/E is 39.2×, based on as-reported figures from SEC (XBRL) filings.

What is Alnylam Pharmaceuticals, Inc.'s Price / Sales?

Alnylam Pharmaceuticals, Inc.'s Price / Sales is 6.3×, based on as-reported figures from SEC (XBRL) filings.

What is Alnylam Pharmaceuticals, Inc.'s Revenue (TTM)?

Alnylam Pharmaceuticals, Inc.'s Revenue (TTM) is $4.8B, based on as-reported figures from SEC (XBRL) filings.

What is Alnylam Pharmaceuticals, Inc.'s Net Income (TTM)?

Alnylam Pharmaceuticals, Inc.'s Net Income (TTM) is $774.7M, based on as-reported figures from SEC (XBRL) filings.

What is Alnylam Pharmaceuticals, Inc.'s EBITDA?

Alnylam Pharmaceuticals, Inc.'s EBITDA is $1.1B, based on as-reported figures from SEC (XBRL) filings.

What is Alnylam Pharmaceuticals, Inc.'s Diluted EPS (TTM)?

Alnylam Pharmaceuticals, Inc.'s Diluted EPS (TTM) is 5.79, based on as-reported figures from SEC (XBRL) filings.

What is Alnylam Pharmaceuticals, Inc.'s EBITDA Margin?

Alnylam Pharmaceuticals, Inc.'s EBITDA Margin is 22.0%, based on as-reported figures from SEC (XBRL) filings.

AKYLA/ Financials

Equity / PHARMACEUTICAL PREPARATIONS

Alnylam Pharmaceuticals, Inc.

XNAS · usd

SIC 2834 · PHARMACEUTICAL PREPARATIONS

FIGI BBG001S7FTC8

227.02▼ 5.66 (-2.43%)

As of 2026-10-12

Price / Volume

Valuation

Market Cap
Enterprise Value: —
Trailing P/E
Price / Sales
EV / Revenue: —
EV / EBITDA: —

Financial Highlights

Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt: —

Trading Information

Previous Close: 232.68
Day's Range: 226.35 – 233.60
52-Week Range: 197.81 – 495.55
Volume: 916.6K
Avg Volume: 1.4M

Share Statistics

Shares Outstanding
Employees: 2,500
Exchange: XNAS
Listed: 2004-05-28

Share count as of July 24, 2026

Alnylam Pharmaceuticals, Inc. (ALNY) Financial Statements

View

Income Statement

Detail

Standard

Period

Quarterly

Loading Income Statement…

Key questions about Alnylam Pharmaceuticals, Inc. (ALNY)

What is Alnylam Pharmaceuticals, Inc.'s Market Cap?: Alnylam Pharmaceuticals, Inc.'s Market Cap is $30.4B, based on as-reported figures from SEC (XBRL) filings.
What is Alnylam Pharmaceuticals, Inc.'s Trailing P/E?: Alnylam Pharmaceuticals, Inc.'s Trailing P/E is 39.2×, based on as-reported figures from SEC (XBRL) filings.
What is Alnylam Pharmaceuticals, Inc.'s Price / Sales?: Alnylam Pharmaceuticals, Inc.'s Price / Sales is 6.3×, based on as-reported figures from SEC (XBRL) filings.
What is Alnylam Pharmaceuticals, Inc.'s Revenue (TTM)?: Alnylam Pharmaceuticals, Inc.'s Revenue (TTM) is $4.8B, based on as-reported figures from SEC (XBRL) filings.
What is Alnylam Pharmaceuticals, Inc.'s Net Income (TTM)?: Alnylam Pharmaceuticals, Inc.'s Net Income (TTM) is $774.7M, based on as-reported figures from SEC (XBRL) filings.
What is Alnylam Pharmaceuticals, Inc.'s EBITDA?: Alnylam Pharmaceuticals, Inc.'s EBITDA is $1.1B, based on as-reported figures from SEC (XBRL) filings.
What is Alnylam Pharmaceuticals, Inc.'s Diluted EPS (TTM)?: Alnylam Pharmaceuticals, Inc.'s Diluted EPS (TTM) is 5.79, based on as-reported figures from SEC (XBRL) filings.
What is Alnylam Pharmaceuticals, Inc.'s EBITDA Margin?: Alnylam Pharmaceuticals, Inc.'s EBITDA Margin is 22.0%, based on as-reported figures from SEC (XBRL) filings.

Akyla / Financials · ALNYAs-filed SEC (XBRL) data